The efficacy of adefovir dipivoxil, entecavir and telbivudine for chronic hepatitis B treatment: A systematic review;Eficácia do adefovir dipivoxil, entecavir e telbivudina para o tratamento da hepatite crônica B: Revisão sistemática

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 43, Issue 4, 2010, Pages 440-451

  Almeida, Alessandra Maciel ^a   Ribeiro, Andréia Queiroz ^b   de Pádua, Cristiane Aparecida Menezes ^c   Brandão, Cristina Mariano Ruas ^a   Andrade, Eli Iôla Gurgel ^a   Cherchiglia, Mariângela Leal ^a   Carmo, Ricardo Andrade ^d   Acurcio, Francisco de Assis ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF VIÇOSA   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO JOÃO DEL REI   (Brazil)

^d FUNDAÇÃO HEMOMINAS   (Brazil)

Author keywords

Adefovir dipivoxil; Chronic hepatitis B; Entecavir; Random and controlled clinical studies; Telbivudine

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PLACEBO; TELBIVUDINE;

ANTIVIRAL RESISTANCE; CLINICAL EVALUATION; CLINICAL TRIAL; CROSS RESISTANCE; DRUG EFFICACY; HEPATITIS B; HUMAN; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

TULIP BREAKING VIRUS;

EID: 77958019432     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0037-86822010000400021     Document Type: Review

References (39)

1. Unaids.org. Report of the global HIV/AIDS epidemic 2007. http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive /2007/default.asp (acessado em Jun/2008).
2. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001;120:1828-1253.
3. Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 2006;10:iii-iv, xi-xiv, 1-183.
4. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
5. Gilson RJ, Chopra KB, Newell AM, Murray-Lyon IM, Nelson MR, Rice SJ, et al. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat 1999;6:387-395.
6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807.
7. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816.
8. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90.
9. Peters MG, Hann Hw H, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101.
10. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-2681.
11. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-1751.
12. Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006;44:1110-1116.
13. Zeng M, Mao Y, Yao G, Wang H, Hou J, Wang Y, et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006;44:108-116.
14. Akyildiz M, Gunsar F, Ersoz G, Karasu Z, Ilter T, Batur Y, et al. Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B. Dig Dis Sci 2007;52:3444-3447.
15. Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008;48:728-735.
16. Vassiliadis TG, Giouleme O, Koumerkeridis G, Koumaras H, Tziomalos K, Patsiaoura K, et al. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg-chronic hepatitis B patients: A 4-year study. J Gastroenterol Hepatol 2009;23:1-7.
17. Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123:1831-1838.
18. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1120.
19. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1110.
20. Ren FY, Piao DM, Piao XX. A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol 2007;13:4264-4267.
21. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-1744.
22. Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients Gastroenterology 2005;129:1198-209.
23. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-2049.
24. De Man RA, Wolters LM, Nevens F, Chua D, Sherman M, Lai CL, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001;34:578-582.
25. Chang TT, Chao YC, Gorbakov VV, Han KH, Gish RG, de Man R, et al. Results of up to 2 years of entecavir vs. lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2009;16:784-789.
26. Shindo M, Chayama K, Mochida S, Toyota J, Tomita E, Kumada H, et al. Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naïve Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial. Hepatol Int 2009;3:445-452.
27. Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, et al. Early hepatitis B virus DNA reduction in hepatitis B e Antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009;49:72-79.
28. Pessôa MG, Gazzard B, Huang AK, Brandão-Mello CE, Cassetti I, Mendes-Corrêa MC, et al. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. AIDS 2008;22:1779-1787.
29. Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007;147:745-754.
30. Lai CL, Lim SG, Brown NA, Zhou XJ, Lloyd DM, Lee YM, et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 2004;40:719-726.
31. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-536.
32. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-2588.
33. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B Gastroenterol 2009;136:486-495.
34. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539.
35. Keeffe EB, Ayoub WS. Current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2008;28:167-177.
36. Tenney DJ, Pokornowski KA, Rose RE, Baldick CJ, Eggers BJ, Fang J, et al. Entecavir at five years shows long-term maintence of high genetic barrier to hepatiteis B virus resistance. Hepatol Int 2008;2 (suppl):S76-S77.
37. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006;44:1656-1665.
38. Colonno RJ, Rose RE, Pokornowski K, Baldick CT, Eggers B, Yu D, et al. Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients. J Hepatol 2007;46(suppl 1):S294.
39. Matthews SJ. Telbivudine for the management of chronic hepatitis B virus infection. Clin Ther 2007;29:2635-2653.